First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience

First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience

Abstract Background The antitumour efficacy of tyrosine kinase inhibitors (TKIs) in lung cancer patients with compound epidermal growth factor receptor (EGFR) mutations has not been resolved. Our study summarizes a single institutional experience of first-generation TKI therapy for lung cancers with...

Full description

Bibliographic Details
Main Authors: Xiangyang Yu, Xuewen Zhang, Zichen Zhang, Yongbin Lin, Yingsheng Wen, Yongqiang Chen, Weidong Wang, Lanjun Zhang
Format: Article
Language:English
Published: Wiley 2018-07-01
Series:Cancer Communications
Subjects:
EGFR
TKIs
Compound mutations
Online Access:http://link.springer.com/article/10.1186/s40880-018-0321-0

Internet

http://link.springer.com/article/10.1186/s40880-018-0321-0

Similar Items